Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach

AIM: To summarise our centre’s experience managing patients with neuroendocrine tumours (NETs) in the first 5 years after the introduction of peptide receptor radionuclide therapy (PRRT) with [(177)Lu]Lu-DOTA-octreotate (LUTATE). The report emphasises aspects of the patient management related to fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, S., Chan, D. L. H., Bernard, E. J., Eslick, M. E., Willowson, K. P., Roach, P. J., Engel, A. F., Maher, R., Clarke, S. J., Agarwal, V., Yasmin, L., De Silva, M., Mascall, S., Conner, A., Nevell, D., Pavlakis, N., Bailey, D. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374703/
https://www.ncbi.nlm.nih.gov/pubmed/37004598
http://dx.doi.org/10.1007/s00432-023-04706-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374703/
https://www.ncbi.nlm.nih.gov/pubmed/37004598
http://dx.doi.org/10.1007/s00432-023-04706-1

Ejemplares similares